Anbio Biotechnology Launches 15-Minute Ultra-Fast PCR System and Chikungunya Rapid Test to Combat Global Disease Outbreaks
核心洞察
Anbio Biotechnology (搜索) has launched the AP-100 Ultra-Fast PCR system (搜索) that delivers laboratory-grade molecular diagnostic results in just 15 minutes without requiring nucleic acid extraction.
The company simultaneously introduced a Chikungunya IgM/IgG Rapid Test (搜索) using immunochromatographic technology to address rising cases of Chikungunya fever (搜索) in tropical and subtropical regions.
The compact 668g AP-100 system covers multiple pathogens including COVID-19 (搜索), Flu A/B, RSV, MP, and ADV, with plans to expand testing capabilities to tuberculosis (搜索) and HPV.
Anbio Biotechnology (搜索) has unveiled two breakthrough diagnostic technologies designed to accelerate infectious disease detection and response capabilities worldwide. The Frankfurt-based company announced the launch of its AP-100 Ultra-Fast PCR system (搜索) alongside a new Chikungunya rapid test, addressing critical gaps in point-of-care molecular diagnostics and emerging vector-borne disease detection.
Revolutionary 15-Minute PCR Technology
The AP-100 Ultra-Fast PCR system (搜索) represents a significant advancement in decentralized molecular diagnostics, delivering laboratory-grade testing capabilities directly to the point of care. The system utilizes an advanced microfluidic thermal cycling system combined with high-efficiency enzymatic amplification chemistry, enabling direct processing of swab samples without the need for nucleic acid extraction.
"Outbreaks demand speed. The AP-100 collapses hours of traditional PCR into minutes, without compromising accuracy," said Michael Lau, CEO of Anbio Biotechnology (搜索).
The compact device weighs just 668 grams, making it suitable for mobile or near-patient testing environments. Its extraction-free workflow eliminates the need for hazardous reagents while maintaining lab-comparable accuracy validated against mainstream PCR platforms. The system currently provides broad pathogen coverage, including COVID-19 (搜索), Flu A/B, RSV, MP, and ADV.
Expanding Molecular Platform Capabilities
While initially focused on respiratory infections, the AP-100 is designed as a flexible molecular platform with expansion capabilities. In line with its global infectious disease strategy, Anbio is developing additional assay panels to include tests for tuberculosis (搜索) (TB) and human papillomavirus (搜索) (HPV), extending the platform's utility from rapid outbreak response to sustained disease management.
The integrated design streamlines sample-to-result workflows, making the system well-suited for deployment in both centralized laboratories and decentralized, point-of-care environments. This versatility addresses the growing need for rapid diagnostic capabilities in both well-resourced and resource-limited healthcare settings.
Chikungunya Rapid Test Addresses Rising Global Cases
In response to recent outbreaks of Chikungunya fever (搜索), Anbio has also launched its Chikungunya IgM/IgG Rapid Test (搜索). As cases continue to rise across tropical and subtropical regions, timely detection and differentiation from other arboviral infections like Dengue (搜索) and Zika (搜索) remain critical for effective patient management and outbreak control.
The test employs immunochromatographic technology to enable reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole blood. This point-of-care diagnostic tool provides clinicians and public health authorities with fast, accessible testing capabilities essential for rapid outbreak response.
Strategic Impact on Global Health Preparedness
The simultaneous launch of both diagnostic technologies strengthens Anbio's infectious disease diagnostics portfolio and supports public health efforts in responding to emerging outbreaks. The combination of ultra-rapid molecular diagnostics and targeted rapid testing for vector-borne diseases addresses two critical areas of global health concern.
"Whether it's vector-borne fevers or respiratory pandemics, we believe diagnostics should move as fast as the threat," Lau added.
With its combination of speed, mobility, and lab-grade precision, Anbio's new-generation point-of-care PCR system strengthens healthcare capacity across diverse settings, advancing global preparedness for infectious disease threats. The company's approach reflects the growing recognition that diagnostic capabilities must match the speed and unpredictability of emerging infectious disease challenges.